Table 1

Patient demographics, tumour data and corresponding SUVmax values

SUVmax
median (mean±SD) (range)
p Value (test)*
Total number of patients765.45 (6.35±3.5) (2–15.9)
 Male46/76 (60.5%)
 Female30/75 (39.5%)
Tumour dimensions
Median (mean±SD) (range)
 
 Tumour thickness (mm)10 (10.1±2.5) (4.7–15.9)
 Maximal base diameter (mm)15 (14.7±3.2) (4.5–20.3)
 Area (mm2)143 (147.4±58.08) (23.7–287.7)
 Volume (mm3)942 (1040.9±570) (87–2546)
COMS classification†
 Medium melanomas12/76 (15.8%)
 Large melanomas64/76 (84.2%)
AJCC classification
 IIA (T1b-d and T2a N0 M0)4/76 (5.3%)3 (2.9±0.6) (2.2–3.6)0.024 (Kruskal–Wallis test)
 IIB (T2b and T3a N0 M0)30/76 (39.5%)4.9 (5.3±2.79) (2.1–13.2)
 IIIA (T2c-d and T3b-c and T4a N0 M0)27/76 (35.5%)6.5 (7.1±3.8) (2–14.7)
 IIIB (T3d and T4b-c N0 M0)13/76 (17.1%)7.1 (7.9±3.7) (3.4–15.9)
 IIIC (T4d-e N0 M0)2/76 (2.6%)7.4 (7.4±5.09) (3.8–11)
Tumour location
 Ciliary body11/76 (18%)7 (7.4±3.2) (3.6–13.3)0.2 (Kruskal–Wallis test)
 Ciliochoroidal30/76 (41%)6 (6.8±3.9) (2–15.9)
 Choroidal35/76 (48%)5 (5.4±2.8) (2.1–13.2)
Histopathology‡
 Epithelioid13/75 (17.3%)6.4 (6.7±3.6) (2.3–14.7)0.923 (Kruskal–Wallis test)
 Spindle A31/75 (41.3%)5.2 (6.3±3.5) (2.1–14.7)
 Spindle B4/75 (5.3%)5.3 (6.3±3.6) (2–15.9)
 Mixed27/75 (36%)4.1 (5.1±2.7) (3.2–9.1)
 High risk35/75 (46.6%)5.7 (6.4±3.5) (2.1–14.7)0.687
 Low risk40/75 (53.3%)4.9 (6.2±3.6) (2–15.9)
Pathology features
 Necrosis6/76 (8%)5.6 (6.9±3.6) (3.1–13.3)0.61
 No necrosis70/76 (92%)5.4 (6.3±3.5) (2–15.9)
 Inflammation13/76 (17%)6.4 (6.6±4.4) (2.1–14.2)0.82
 No inflammation63/76 (83%)5.3 (6.3±3.3) (2–15.9)
 Retinal detachment46/76 (60.5%)6.3 (6.8±4.8) (2–15.9)0.15
 No retinal detachment30/76 (39.5%)4.7 (5.5±2.9) (2.1–14.2)
 Haemorrhage10/76 (13%)4 (5.8±3.8) (2.8–14.7)0.56
 No haemorrhage66/76 (87%)5.7 (6.4±3.5) (2–15.9)
Cytogenetic analysis§
 Chromosome 3
  Monosomy 335/73 (47.9%)6.5 (7±3.3) (2–15.9)0.043
  Disomy 335/73 (47.9%)4.3 (5.6±3) (2.2–14.7)
  Failure3/73 (4%)0.49
 Chromosome 8
  Gain of 852/73 (71.2%)6.3 (6.1±3) (2–15.9)
  Disomy 818/73 (24.7%)4.1 (6.2±4.2) (2.4–14.7)
  Failure3/73 (4%)
  Monosomy 3/gain of 833/73 (45%)6.55 (7.2±3.2) (2–15.9)
  Monosomy 3/disomy 82/73 (2.7%)2.45 (2.45±0.5) (2.1–2.8)0.015¶
  Disomy 3/gain of 819/73 (26%)4.3 (5.1±3.1) (2.2–14.2)
  Disomy 3/disomy 816/73 (22%)4.2 (6.3±4) (2.7–14.7)0.354
  • *Mann–Whitney test unless noted.

  • †Small melanoma (1.5–2.4 mm in thickness and 5–16 mm in diameter), medium melanoma (2.5–10 mm in thickness and ≤16 mm in diameter) and large melanoma (>10 mm in thickness and >16 mm in diameter).

  • ‡Available in 75 tumours.

  • §Available in 73 tumours.

  • ¶Versus disomy 3/gain 8.

  • AJCC, American Joint Committee on Cancer; COMS, Collaborative Ocular Melanoma Study; SUVmax, maximal standardised uptake value.